RecruitingPhase 3NCT04629833

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Studying Best vitelliform macular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
medac GmbH
Principal Investigator
Ann-Kristin Möller
medac GmbH
Intervention
MC0518(biological)
Enrollment
210 target
Eligibility
12 years · All sexes
Timeline
20212030

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04629833 on ClinicalTrials.gov

Other trials for Best vitelliform macular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Best vitelliform macular dystrophy

← Back to all trials